Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.

Grose R, Fantl V, Werner S, Chioni AM, Jarosz M, Rudling R, Cross B, Hart IR, Dickson C.

EMBO J. 2007 Mar 7;26(5):1268-78. Epub 2007 Feb 15.

2.

Fibroblast growth factor signalling in mouse mammary gland development.

Spencer-Dene B, Dillon C, Fantl V, Kerr K, Petiot A, Dickson C.

Endocr Relat Cancer. 2001 Sep;8(3):211-7. Review.

PMID:
11566612
3.

Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors.

Dickson C, Spencer-Dene B, Dillon C, Fantl V.

Breast Cancer Res. 2000;2(3):191-6. Epub 2000 Mar 25. Review.

4.

Fibroblast growth factor signalling and cyclin D1 function are necessary for normal mammary gland development during pregnancy. A transgenic mouse approach.

Fantl V, Creer A, Dillon C, Bresnick J, Jackson D, Edwards P, Rosewell I, Dickson C.

Adv Exp Med Biol. 2000;480:1-7. Review.

PMID:
10959404
5.

Mammary gland oncogenes as indicators of pathways important in mammary gland development.

Dickson C, Creer A, Fantl V.

Oncogene. 2000 Feb 21;19(8):1097-101. Review.

6.

Impaired mammary gland development in Cyl-1(-/-) mice during pregnancy and lactation is epithelial cell autonomous.

Fantl V, Edwards PA, Steel JH, Vonderhaar BK, Dickson C.

Dev Biol. 1999 Aug 1;212(1):1-11.

7.

Amplification, expression, and steroid regulation of the preprogalanin gene in human breast cancer.

Ormandy CJ, Lee CS, Ormandy HF, Fantl V, Shine J, Peters G, Sutherland RL.

Cancer Res. 1998 Apr 1;58(7):1353-7.

8.

Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C.

Genes Dev. 1995 Oct 1;9(19):2364-72.

9.

Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer.

Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G.

Cancer Lett. 1995 Mar 23;90(1):43-50. Review.

PMID:
7720042
10.

Chromosome 11q13 markers and D-type cyclins in breast cancer.

Peters G, Fantl V, Smith R, Brookes S, Dickson C.

Breast Cancer Res Treat. 1995;33(2):125-35. Review.

PMID:
7749140
11.

Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G.

Cancer Res. 1994 Apr 1;54(7):1812-7.

12.

Fgf-3, an oncogene in murine breast cancer.

Dickson C, Fantl V.

Cancer Treat Res. 1994;71:331-43. Review. No abstract available.

PMID:
7946957
13.

Chromosome 11q13 abnormalities in human breast cancer.

Fantl V, Smith R, Brookes S, Dickson C, Peters G.

Cancer Surv. 1993;18:77-94. Review.

PMID:
8013002
14.

Nonuniform expression of a mouse mammary tumor virus-driven int-2/Fgf-3 transgene in pregnancy-responsive breast tumors.

Stamp G, Fantl V, Poulsom R, Jamieson S, Smith R, Peters G, Dickson C.

Cell Growth Differ. 1992 Dec;3(12):929-38.

15.

D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1.

Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A, Peters G.

Oncogene. 1991 Mar;6(3):439-44.

PMID:
2011398
16.

Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer.

Fantl V, Richards MA, Smith R, Lammie GA, Johnstone G, Allen D, Gregory W, Peters G, Dickson C, Barnes DM.

Eur J Cancer. 1990 Apr;26(4):423-9.

PMID:
2141507
17.

Effects of a monoclonal antibody against progesterone, on embryo transport, development and implantation in laboratory mice.

Vinijsanun A, Martin L, Wang DY, Fantl VE.

Reprod Fertil Dev. 1990;2(4):395-405.

PMID:
2217896
18.

Measurement of human corticosteroid binding globulin by enzyme-linked immunoassay.

Fantl VE, Wang DY, Mockridge CI.

J Steroid Biochem. 1988 Aug;31(2):187-93.

PMID:
3404988
19.

Urinary epidermal growth factor excretion and breast cancer risk.

Wang DY, Mockridge CI, Fantl VE, de Stavola B, Allen DS, Thomas BS, Moore JW, Bulbrook RD, Gravelle IH, Kwa HG, et al.

Eur J Cancer Clin Oncol. 1988 Jun;24(6):1049-53.

PMID:
3261690
20.

Salivary oestradiol and progesterone levels in premenopausal women with breast cancer.

Wang DY, Fantl VE, Habibollahi F, Clark GM, Fentiman IS, Hayward JL, Bulbrook RD.

Eur J Cancer Clin Oncol. 1986 Apr;22(4):427-33.

PMID:
3732349
21.

A solid-phase radioimmunoassay of serum dehydroepiandrosterone sulphate using a monoclonal antibody.

Knyba RE, Wang DY, Fantl VE.

J Steroid Biochem. 1985 Mar;22(3):427-9.

PMID:
3157835
22.
23.

Characterisation of monoclonal antibodies raised against testosterone.

Fantl VE, Wang DY.

J Steroid Biochem. 1983 Nov;19(5):1605-10.

PMID:
6645496
24.

The production of high affinity monoclonal antibodies to progesterone.

Fantl VE, Wang DY, Knyba RE.

J Steroid Biochem. 1982 Aug;17(2):125-30.

PMID:
7109599
25.

Immunological studies with human aortic elastin.

Barnard K, Partridge SM, Whiting AH, Fantl V, McCullagh KG.

Connect Tissue Res. 1982;9(4):233-40.

PMID:
6181938
26.

Production and characterisation of a monoclonal antibody to progesterone.

Fantl VE, Wang DY, Whitehead AS.

J Steroid Biochem. 1981 Apr;14(4):405-7. No abstract available.

PMID:
6785530
27.
28.

Urinary pregn-5-ene-3 ,16 ,20 -triol in adrenal dysfunction.

Fantl V, Booth M, Gray CH.

J Endocrinol. 1973 Apr;57(1):135-42. No abstract available.

PMID:
4701165
29.

Isolation of urinary 3, 16 -dihydroxyandrost-5-en-17-one in adrenal carcinoma.

Fantl V.

J Endocrinol. 1973 Mar;56(3):615-6. No abstract available.

PMID:
4733093

Supplemental Content

Support Center